Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

SAN FRANCISCO -- As more people are getting vaccinated, medical experts in the United Kingdom and the U.S are holding trials to find out if giving two doses of a different COVID vaccine improves your ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...